In an analysis carried out by Alliance for Clinical Trials in Oncology no complete responses were observed among TP53-mutated AMLs, while some complete responses were observed among high-risk AML patients with non TP53-mutated AMLs [65]. Here, TP53 is linked to acute myeloid leukemia.